person · Reporting owner

JONAS JEFFREY M

Disclosed activity across 4 companies

Tapewire entity: 43270
SEC CIK: 0001042021

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COMPASS Pathways plcCMPS · Entity 4567	Director	May 27, 2026	May 29, 2026
Sage Therapeutics, Inc.SAGE · Entity 77038	Director	June 10, 2024	June 11, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COMPASS Pathways plc

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26	Direct	21,110	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Sage Therapeutics, Inc.

Report date June 10, 2024 · Filed June 11, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2034-06-09	Direct	12,500	Reported balance After 2024-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Generation Bio Co.

Report date February 09, 2026 · Filed February 09, 2026

Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87	Direct	Reported balance After 2026-02-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the "Cash Amount") (each such option, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.92	Direct	Reported balance After 2026-02-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-09 · Disposition to issuer · Disposed 4,246 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00	Direct	Reported balance After 2026-02-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90	Direct	Reported balance After 2026-02-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90	Direct	Reported balance After 2026-02-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30	Direct	Reported balance After 2026-02-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20	Direct	Reported balance After 2026-02-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was less than $4.2913 (the "Cash Amount") (each such option, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Karuna Therapeutics, Inc.

Report date March 15, 2024 · Filed March 18, 2024

Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-03-18 transaction · row 1 1 source row Row 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2028-09-30	Direct	Reported balance After 2024-03-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-18 · Disposition to issuer · Disposed 19,893 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15	Direct	Reported balance After 2024-03-18 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14	Direct	Reported balance After 2024-03-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19	Direct	Reported balance After 2024-03-18 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2029-06-26	Direct	Reported balance After 2024-03-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-18 · Disposition to issuer · Disposed 16,250 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.
Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $97.59 · Expires 2030-06-04	Direct	Reported balance After 2024-03-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-18 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F4: These Options are fully vested.

F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2023 Filed Jan 5, 2023 21:29 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	2,501	$0.00 Strike: $28.63	$0.00	Disclosure SEC source: 0001562180-23-000234 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,499 Underlying: Common Stock · 2,501 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option vested in full on February 8, 2020. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:29 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	2,501	$28.63	$71,603.63	Disclosure SEC source: 0001562180-23-000234 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2022 Filed Jun 16, 2022 20:40 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	5,000	$0.00 Strike: $102.96	$0.00	Disclosure SEC source: 0001593968-22-001150 · primary_01.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:06 UTC	Generation Bio Co. GBIO · Entity 67174	GrantStock Option (right to buy) · Derivative	19,200	$0.00 Strike: $6.19	$0.00	Disclosure SEC source: 0001415889-22-006481 · form4-06132022_040633.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 19,200 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders. Read SEC document
April 27, 2022 Filed Apr 29, 2022 12:40 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	30,944	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-22-003565 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,643 Underlying: Common Stock · 30,944 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017. Read SEC document
April 27, 2022 Filed Apr 29, 2022 12:40 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	30,944	$0.45	$13,924.80	Disclosure SEC source: 0001562180-22-003565 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2022 Filed Feb 18, 2022 21:10 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-22-001626 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,587 Underlying: Common Stock · 4,000 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017. Read SEC document
February 17, 2022 Filed Feb 18, 2022 21:10 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	4,000	$0.45	$1,800.00	Disclosure SEC source: 0001562180-22-001626 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 11, 2022 Filed Feb 15, 2022 21:41 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	15,200	$0.00 Strike: $43.04	$0.00	Disclosure SEC source: 0001562180-22-001473 · primarydocument.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,200 Underlying: Common Stock · 15,200 shares Expires 2032-02-11 F1 · derivative.exercise_date: The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 3,800 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 11,400 shares vesting in 36 equal monthly installments thereafter. Read SEC document
October 19, 2021 Filed Oct 21, 2021 20:03 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Tax withholdingCommon Stock	4,374	$40.29	$176,228.46	Disclosure SEC source: 0001562180-21-006597 · primarydocument.xml · nonDerivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,863 Read SEC document
October 19, 2021 Filed Oct 21, 2021 20:03 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-21-006597 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,237 F1 · shares: On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 10,000 shares. Read SEC document
June 16, 2021 Filed Jun 17, 2021 13:13 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-21-004340 · primarydocument.xml · derivative · entry 4 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,587 Underlying: Common Stock · 12,000 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017. Read SEC document
June 16, 2021 Filed Jun 17, 2021 13:13 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	12,000	$0.45	$5,400.00	Disclosure SEC source: 0001562180-21-004340 · primarydocument.xml · nonDerivative · entry 3 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2021 Filed Jun 23, 2021 20:28 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	8,500	$0.00 Strike: $128.01	$0.00	Disclosure SEC source: 0001593968-21-001680 · primary_01.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders. Read SEC document
June 15, 2021 Filed Jun 17, 2021 13:13 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Tax withholdingCommon Stock	3,093	$58.80	$181,868.40	Disclosure SEC source: 0001562180-21-004340 · primarydocument.xml · nonDerivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,237 Read SEC document
June 15, 2021 Filed Jun 17, 2021 13:13 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001562180-21-004340 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,330 F1 · shares: On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 25,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 10,000 shares. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:13 UTC	Generation Bio Co. GBIO · Entity 67174	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $26.59	$0.00	Disclosure SEC source: 0001415889-21-002955 · form4-06112021_010617.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders. Read SEC document
February 10, 2021 Filed Feb 12, 2021 21:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	34,000	$0.00 Strike: $82.27	$0.00	Disclosure SEC source: 0001562180-21-001128 · primarydocument.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 8,500 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 25,500 shares vesting in 36 equal monthly installments thereafter. Read SEC document
January 27, 2021 Filed Jan 28, 2021 21:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	1,800	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-21-000571 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,587 Underlying: Common Stock · 1,800 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017. Read SEC document
January 27, 2021 Filed Jan 28, 2021 21:02 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	1,800	$0.45	$810.00	Disclosure SEC source: 0001562180-21-000571 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2020 Filed Jun 15, 2020 21:27 UTC	Generation Bio Co. GBIO · Entity 67174	GrantStock Option (right to buy) · Derivative	52,000	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0000899243-20-016558 · doc4.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:39 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantOption (right to buy) · Derivative	12,500	$0.00 Strike: $97.59	$0.00	Disclosure SEC source: 0001593968-20-001423 · primary_01.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 4, 2021, and (ii) the 2021 annual meeting of the Issuer's stockholders. Read SEC document
April 28, 2020 Filed Apr 30, 2020 20:44 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	15,385	$0.00 Strike: $39.87	$0.00	Disclosure SEC source: 0001562180-20-003226 · primarydocument.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,385 Underlying: Common Stock · 15,385 shares Expires 2030-04-28 F1 · derivative.exercise_date: The securities awarded on April 28, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 25% of the shares of common stock underlying this stock option award will vest on April 28, 2021, and the remaining 75% of the shares of common stock underlying this stock option award will vest on April 28, 2022, so long as the Reporting Person remains an employee or consultant of the Company on each of the applicable vesting dates. Read SEC document
February 12, 2020 Filed Feb 14, 2020 21:56 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $68.87	$0.00	Disclosure SEC source: 0001562180-20-001240 · primarydocument.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: The securities awarded on February 12, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 12,500 shares of common stock shall vest on the one year anniversary of February 12, 2020, with 37,500 shares vesting in 36 equal monthly installments thereafter. Read SEC document
December 09, 2019 Filed Dec 11, 2019 01:04 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	PurchaseCommon Stock	7,500	$64.20	$481,500.00	Disclosure SEC source: 0001562180-19-005990 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,530 F1 · price: This transaction was executed in multiple trades at prices ranging from $63.88 USD to $64.49 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 11, 2019 Filed Sep 12, 2019 21:00 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	4,600	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-19-004788 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,387 Underlying: Common Stock · 4,600 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017. Read SEC document
September 11, 2019 Filed Sep 12, 2019 21:00 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	4,600	$0.45	$2,070.00	Disclosure SEC source: 0001562180-19-004788 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 25, 2019 Filed Jul 30, 2019 00:00 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Tax withholdingCommon Stock	1,685	$161.38	$271,925.30	Disclosure SEC source: 0001562180-19-004092 · primarydocument.xml · nonDerivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,430 Read SEC document
July 25, 2019 Filed Jul 30, 2019 00:00 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-004092 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,115 F1 · shares: On February 13, 2019, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 25,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on July 25, 2019, resulting in the vesting of the PSU as to 5,000 shares. Read SEC document
July 16, 2019 Filed Jul 17, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	27,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-19-003968 · primarydocument.xml · derivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,987 Underlying: Common Stock · 27,000 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017. Read SEC document
July 16, 2019 Filed Jul 17, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	27,000	$0.45	$12,150.00	Disclosure SEC source: 0001562180-19-003968 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:17 UTC	Karuna Therapeutics, Inc. KRTX · Entity 92934	GrantStock Option (Right to Buy) · Derivative	16,250	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-19-018724 · doc4.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 27, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 21, 2019 Filed Jun 25, 2019 21:16 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	23,100	$0.00 Strike: $47.70	$0.00	Disclosure SEC source: 0001562180-19-003636 · primarydocument.xml · derivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 Underlying: Common Stock · 23,100 shares Expires 2027-02-06 F1 · derivative.exercise_date: On February 6, 2017, the reporting person was granted an option to purchase 70,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on June 21, 2019, resulting in the vesting of the option as to 23,100 shares. Read SEC document
May 29, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	475	$171.39	$81,410.54	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 9 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,115 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: This transaction was executed in multiple trades at prices ranging from $171.20 USD to $172.00 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 29, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	400	$170.40	$68,158.00	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 8 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,590 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: This transaction was executed in multiple trades at prices ranging from $170.00 USD to $170.83 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 29, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	200	$169.16	$33,832.00	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 7 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,990 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: This transaction was executed in multiple trades at prices ranging from $168.82 USD to $169.50 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	35,736	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · derivative · entry 10 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,987 Underlying: Common Stock · 35,736 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	2,545	$177.62	$452,033.23	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 6 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,190 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: This transaction was executed in multiple trades at prices ranging from $177.18 USD to $177.98 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	11,662	$176.44	$2,057,673.60	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 5 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,735 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: This transaction was executed in multiple trades at prices ranging from $176.05 USD to $177.01 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	16,651	$175.72	$2,925,880.42	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 4 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,397 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $175.05 USD to $176.04 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	28,293	$174.48	$4,936,667.32	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 3 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,048 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $173.99 USD to $174.93 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	25,510	$173.62	$4,428,933.96	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 2 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,341 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $172.99 USD to $173.98 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 28, 2019 Filed May 29, 2019 20:01 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	35,736	$0.45	$16,081.20	Disclosure SEC source: 0001562180-19-003161 · primarydocument.xml · nonDerivative · entry 1 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	40,356	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · derivative · entry 15 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,723 Underlying: Common Stock · 40,356 shares Expires 2023-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	950	$177.76	$168,872.00	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 13 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,115 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: This transaction was executed in multiple trades at prices ranging from $177.47 USD to $178.16 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	2,518	$176.80	$445,182.40	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 12 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,065 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: This transaction was executed in multiple trades at prices ranging from $176.46 USD to $177.39 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	3,974	$175.79	$698,589.46	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 11 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,583 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: This transaction was executed in multiple trades at prices ranging from $175.45 USD to $176.42 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	24,966	$175.02	$4,369,549.32	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 10 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,557 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: This transaction was executed in multiple trades at prices ranging from $174.45 USD to $175.43 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	7,948	$174.05	$1,383,349.40	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 9 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,523 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: This transaction was executed in multiple trades at prices ranging from $173.43 USD to $174.42 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 24, 2019 Filed May 24, 2019 22:24 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	40,356	$0.45	$18,160.20	Disclosure SEC source: 0001562180-19-003105 · primarydocument.xml · nonDerivative · entry 8 JONAS JEFFREY M · CIK 0001042021 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.